Accueil・Liste d'Actions・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Fermé

SecteurSoins de santé

19.11 1.16

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

18.8

Max

19.34

Chiffres clés
By Trading Economics
Revenu	-24M -54M
Ventes	-2.5M 305M
BPA	-0.15
Marge bénéficiaire	-17.851
Employés	3,100
EBITDA	-24M -32M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+175.38% upside

Dividendes
By Acuity
Prochains Résultats	11 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-1B 3.7B
Ouverture précédente	17.95
Clôture précédente	19.11

Sentiment de l'Actualité

By Acuity

100%

320 / 340 Classement par Healthcare

Legend Biotech Corp ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 août 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31 juil. 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30 juil. 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29 juil. 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28 juil. 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27 juil. 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24 juil. 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22 juil. 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21 juil. 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20 juil. 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Comparaison

Variation de prix

Legend Biotech Corp ADR prévision

Objectif de Prix

By TipRanks

175.38% hausse

Prévisions sur 12 Mois

Moyen 52.35 USD 175.38%

Haut 80 USD

Bas 28 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.